BR0109602A - Glóbulos de liberação controlada contendo estavudina - Google Patents

Glóbulos de liberação controlada contendo estavudina

Info

Publication number
BR0109602A
BR0109602A BR0109602-8A BR0109602A BR0109602A BR 0109602 A BR0109602 A BR 0109602A BR 0109602 A BR0109602 A BR 0109602A BR 0109602 A BR0109602 A BR 0109602A
Authority
BR
Brazil
Prior art keywords
globules
stavudine
controlled release
extrusion
coated
Prior art date
Application number
BR0109602-8A
Other languages
English (en)
Inventor
Robert Abramowitz
Denise M O'donoghue
Nemichand B Jain
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0109602A publication Critical patent/BR0109602A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"GLóBULOS DE LIBERAçãO CONTROLADA CONTENDO ESTAVUDINA". Apresentam-se formas de dosagem prolongada de estavudina compreendendo glóbulos formados por extrusão-esferonização e revestidos com um revestimento impermeabilizante. Os glóbulos também são revestidos com um revestimento de liberação modificada, de modo que uma cápsula de gelatina dura contendo esses glóbulos proporcione níveis sang³íneos de estavudina durante aproximadamente 24 horas. Os glóbulos são preparados com uma mistura seca de estavudina, um agente de esferonização, um diluente adequado e uma quantidade estabilizadora de estearato de magnésio. Descobriu-se que o estearato de magnésio, em contraste com outros adjuvantes farmacêuticos similares, estabiliza a estavudina contra a degradação devida à hidrólise na presença da quantidade limitada de água necessária para o processo de extrusão-esferonização. Também estão incluídos no âmbito da invenção cápsulas de gelatina dura contendo, além dos glóbulos de estavudina, glóbulos similares contendo outros agentes terapêuticos utilizados para tratar infecções retrovirais.
BR0109602-8A 2000-03-30 2001-03-29 Glóbulos de liberação controlada contendo estavudina BR0109602A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19358800P 2000-03-30 2000-03-30
PCT/US2001/010078 WO2001074329A2 (en) 2000-03-30 2001-03-29 Sustained release beadlets containing stavudine

Publications (1)

Publication Number Publication Date
BR0109602A true BR0109602A (pt) 2004-06-29

Family

ID=22714247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109602-8A BR0109602A (pt) 2000-03-30 2001-03-29 Glóbulos de liberação controlada contendo estavudina

Country Status (26)

Country Link
US (1) US7135465B2 (pt)
EP (1) EP1267879A2 (pt)
JP (1) JP2003528905A (pt)
KR (1) KR20030011805A (pt)
CN (1) CN1187052C (pt)
AR (1) AR027748A1 (pt)
AU (1) AU2001249591A1 (pt)
BG (1) BG107157A (pt)
BR (1) BR0109602A (pt)
CA (1) CA2404687A1 (pt)
CZ (1) CZ20023003A3 (pt)
EE (1) EE200200564A (pt)
GE (1) GEP20043285B (pt)
HU (1) HUP0302631A2 (pt)
IL (1) IL151475A0 (pt)
LT (1) LT5045B (pt)
LV (1) LV12939B (pt)
MX (1) MXPA02009534A (pt)
NO (1) NO20024645D0 (pt)
NZ (1) NZ522250A (pt)
PE (1) PE20011179A1 (pt)
PL (1) PL366089A1 (pt)
RU (1) RU2239435C2 (pt)
SK (1) SK12822002A3 (pt)
WO (1) WO2001074329A2 (pt)
ZA (1) ZA200207760B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
PL373148A1 (en) * 2002-06-27 2005-08-22 Cilag Ag Spherical pellet formulations
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
KR20080053317A (ko) * 2005-08-31 2008-06-12 씨아이피엘에이 엘티디. 라미부딘, 스타부딘 및 네비라핀을 포함하는 약학적 조합물
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2636436C (en) 2006-01-20 2014-04-01 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tmc278
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CN102319181B (zh) * 2011-09-08 2014-07-16 广东大华农动物保健品股份有限公司 一种微囊型动物药品的包被工艺
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
CN106488778A (zh) * 2014-07-17 2017-03-08 陶氏环球技术有限责任公司 乙基纤维素分散体和薄膜
CN105511174A (zh) * 2016-01-05 2016-04-20 深圳市华星光电技术有限公司 液晶显示面板和显示装置

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671963A (en) 1983-10-28 1987-06-09 Germino Felix J Stearate treated food products
US4670270A (en) 1984-05-07 1987-06-02 Germino Felix J Stearate treated food products
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
EP0619731B1 (en) 1991-12-30 2000-10-04 Fmc Corporation Microcrystalline cellulose spheronization composition
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
GB9403449D0 (en) 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
ES2139195T3 (es) 1994-03-07 2000-02-01 Vertex Pharma Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
EP0814806A1 (en) 1995-02-23 1998-01-07 Janssen Pharmaceutica N.V. Use of fused benzothiazoles as neuroprotectants
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EA001957B1 (ru) 1995-12-15 2001-10-22 Вироден Фармасьютикал Холдингс (Проприетэри) Лимитед КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДа
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5883252A (en) 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en) 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
AU721653B2 (en) 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
ES2236943T3 (es) * 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
BR9911457A (pt) 1998-06-24 2001-12-11 Univ Emory Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
WO2000057870A2 (en) 1999-03-31 2000-10-05 The Procter & Gamble Company Viral treatment
US6136835A (en) 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
CZ20023003A3 (cs) 2002-11-13
AR027748A1 (es) 2003-04-09
RU2239435C2 (ru) 2004-11-10
SK12822002A3 (sk) 2003-02-04
WO2001074329A3 (en) 2002-05-10
GEP20043285B (en) 2004-07-26
RU2002126540A (ru) 2004-03-27
AU2001249591A1 (en) 2001-10-15
WO2001074329A2 (en) 2001-10-11
BG107157A (en) 2003-06-30
NO20024645L (no) 2002-09-27
CN1187052C (zh) 2005-02-02
NO20024645D0 (no) 2002-09-27
HUP0302631A2 (hu) 2003-11-28
LV12939B (en) 2003-04-20
MXPA02009534A (es) 2003-05-14
LT2002099A (en) 2003-04-25
KR20030011805A (ko) 2003-02-11
PL366089A1 (en) 2005-01-24
EP1267879A2 (en) 2003-01-02
CN1420774A (zh) 2003-05-28
US7135465B2 (en) 2006-11-14
CA2404687A1 (en) 2001-10-11
IL151475A0 (en) 2003-04-10
EE200200564A (et) 2004-06-15
ZA200207760B (en) 2004-01-30
NZ522250A (en) 2004-09-24
JP2003528905A (ja) 2003-09-30
LT5045B (lt) 2003-08-25
PE20011179A1 (es) 2001-12-06
US20020002147A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AR027748A1 (es) Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BR9812018A (pt) Composições farmacêuticas de meloxicam com solubilidade e biodisponibilidade melhoradas
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BR9914109A (pt) Composições antibióticas para tratamento dos olhos, ouvidos e nariz
BR9814643A (pt) Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
BRPI9509286B8 (pt) microcápsulas medicamentosas e/ou nutricionais para administração per si.
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0412298A (pt) inibidores de cascata de complemento conjugado
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
KR900015722A (ko) N-(3,4-디메톡시신나모일) 안트라닐산을 함유하는 약제 조성물
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
PT1056454E (pt) Utilizacao de compostos macrolido para o tratamento do glaucoma
BRPI0015939B8 (pt) sistema terapêutico transdérmico com estabilidade aperfeiçoada e processo para a sua preparação
BR9914158A (pt) Composição antibiótica para o tratamento dos olhos, ouvidos e nariz
BR0211430A (pt) Compostos ou seus sais, processos para prevenção ou tratamento de condições, processo para prevenção ou tratamento de uma doença e usos de compostos
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
NZ506408A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A., E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.